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Sir,
I read the article by Iqbal et al. published in JCPSP
2013, Vol. 23 (11): 784-786 with great interest.1 The
authors aimed to make a comparison between serology
and histology for detection of Helicobacter (H.) pylori
infection. Among the 50 study subjects, 30 (60%)
subjects were found positive for H. pylori infection with
serological testing. Twenty-five (50%) subjects were
identified positive for H. Pylori infection with histo-
pathological diagnosis. Among 30 seropositive subjects,
5 subjects found no evidence of H. pylori infection with
histological evaluation. As a result, the authors reported
a substantial agreement between serology and histo-
pathology to detect the H. pylori infection (Cohen's
Kappa coefficient, 0.72). I appreciate the efforts of the
authors but some points need to be clarified before
making a judgement about the results of the study.
In patients with atrophic gastritis, the diagnosis of active
H. pylori infection is difficult. During the progression
course of atrophy, the density of H. pylori in the stomach
mucosa decreases, and during the late stages of
atrophy the infection may completely disappear.2 The
density of H. pylori colonization may significantly
influence test results. Additionally, the endoscopic
diagnosis of H. pylori infection in patients with bleeding
or perforated duodenal ulcers is limited by a decreased
sensitivity in standard invasive tests, rapid urease test
and histology.3
The prepyloric antrum has been the preferred site of
biopsy. The sensitivity of distal antral biopsy was
96 - 97% and the sensitivity of two biopsies from virtually
anywhere in the stomach was 100%.4 The staining
technique used for the identification of H. pylori is as
important as the site and number of biopsies. For
example sole reliance on haematoxylin and eosin when
the density of H. pylori is low, is unwise and giemsa
staining may improve the diagnostic accuracy in these
circumstances.3
Considering the data presented above I would like to ask
the authors of the present series as to how many
biopsies were obtained and what was the gastric site of
diagnosis? What were the endoscopic diagnosis in
these patients? Which stains were used for the
histopathological diagnosis of H. pylori? Was there any
clinical parameter that could influence the results of the
histopathological evaluation, e.g. previous H. pylori
treatment or recent use of proton pump inhibitor?
I think the answers to these questions would improve the
power of this study.
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Sir,
We read the recent report “A substantial agreement
found between serology and histopathology results to
detect the Helicobacter pylori infection” by Iqbal et al.
with reservation. Fifty subjects were included by non-
probability purposive sampling from laboratory data who
had serological testing of H. pylori IgG antibody, prior to
histological evaluation of endoscopic gastric or/and
duodenal biopsies. Thirty (60%) subjects were found
positive for H. pylori infection with serological testing.
However, 25 (50%) subjects were identified positive for
H. pylori with histopathological diagnosis. Among 30
seropositive subjects, 5 subjects found no evidence of
H. pylori infection with histological evaluation. Authors
concluded that “serology assesses the presence of
H. pylori in the stomach even when the bacteria are
irregularly distributed on the gastric mucosa and may be
missed on taking biopsy”.
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Agreement Between Serology
and Histology for Detection of
Helicobacter pylori Infection
The choice of diagnostic test for H. pylori depends upon
cost, availability, clinical situation, population prevalence
of infection, pretest probability of infection, factors that
influence certain test results such as proton pump
inhibitors and antibiotics. Methods available for detecting
H. pylori infection include serology, rapid urease test,
histology, 13/14 C-urea breath test (UBT) and
polymerase chain reaction. The results of rapid urease
test, histology and UBT are all affected by previous
intake of antibiotics, acid reducing drugs e.g., proton
pump inhibitor and histamine-2-receptor blockers. It was
not informed whether the biopsy samples were collected
from patients who were on any of these medicines
previously.1-3
On the basis of a serology, one can not be able to decide
whether to treat or not. A positive result with serology
does not tell whether the patient has current infection or
had a past infection that is now cured.4,5 Serology is
inferior to active testing in sensitivity and especially
specificity. The false-positive results include both actual
false positives for active infection and true positive for
antibody, not infected. The drawbacks are treatment of
people who are not actively infected, waste of resources,
inconveniences to patients, contribution to antibiotic
resistance. This method is reliable only for population
surveys and not for individual patients. Serum IgG
against H. pylori suggests gastric mucosal immuno-
logical response against H. pylori infection. It certainly
does not assess the presence of H. pylori irregularly
distributed on the gastric mucosa something that is done
by the UBT in the gastric mucosa. The current practice
of using positive H. pylori serology for commencing
treatment needs to be discouraged in primary care
practice.
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Authors’ Reply (to both letters):
We thank the readers for their comments and the
opportunity to clarify a number of points from our work.
We looked at the agreement between serology and
histology of H. pylori infection. In our small series of
cases, we are saying that serological testing for IgG
provides an inexpensive, non-invasive and convenient
method to detect H. pylori infection having substantial
agreement with histology in our setting. It is important to
understand that ideally non-invasive testing should be
limited to H. pylori tests that detect active infection only
which include stool antigen test and urea breath test.
Serologic antibody tests do not distinguish between
currently active infection with a past exposure and an
infection that has been cured.
Endoscopic biopsy remains a gold standard diagnostic
test for active Helicobacter pylori (H. pylori) infection;
however, it is an invasive and costly technique. By
precisely guiding diagnosis and treatment; histology
potentially reduced the number of patients inappro-
priately treated but the cost-effectiveness analysis
supports the continued practice of initial non-invasive
approaches to guide antibiotic use.
World over, there is a shift in diagnosis from testing with
IgG to H. pylori antigen testing of human stool by
enzyme immunoassay or immune chromatography and
urea breath test, which measures radio-labeled carbon
dioxide by a mass spectrometer or scintillation counter.
Both the tests are currently not available in our setup
and have their limitations. Serological testing can be
regarded as representing a primary approach for
evaluation of H. pylori status in patients with uncompli-
cated dyspeptic disease, who do not immediately
require endoscopic studies or previously not treated for
peptic ulcer disease, especially in a setup like ours
where the seroprevalence of H. pylori is about 58-60%.
H. pylori serological tests detect antibodies to H. pylori
with a sensitivity and specificity of approximately 90%.
In populations with high disease prevalence, the positive
predictive value of the test rises dramatically, thus
facilitating diagnosis and subsequent treatment if
invasive testing is not required or opted.
Moreover, the management of H. pylori infection
requires a multi-disciplinary approach and it is strongly
recommended that there should be close local
collaboration and interaction between primary care
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physicians, specialist gastroenterologists, micro-
biologists and possibly public health doctors. Non-
invasive tests are options of choice in primary care
setting. Adding testing for H. pylori infection to history-
taking has been recommended in patients at high risk of
having peptic ulcer disease. It would avoid endoscopies
in some patients and lead to more accurate treatment of
peptic ulcer disease in most patients. Furthermore, a
proportion of dyspeptic patients presenting in primary
care for the first time are patients with peptic ulcer
disease who are H. pylori positive and could get benefit
from diagnosis and consequent treatment of the
infection.
Infection with H. pylori can be patchy, and, as a result,
multiple biopsy specimens may be necessary for
diagnosis with endoscopy. However, this is at the
discretion of gastroenterologist performing the endo-
scopy. In our series of cases atleast two biopsies were
taken from gastric antrum. In contrast, serology
demonstrates the systemic humoral response and thus
presence or absence of disease, irrespective of pattern
of distribution of H. pylori, in the gastric mucosa.
Our article is based on retrospective analysis of data
and unfortunately we do not have a robust explanation
for the missing clinical information. Due to the absence
of a national health system the complete clinical
information by physicians like the previous treatment
and use of proton pump inhibitors is hardly provided. We
propose performing a prospective clinical trial that we
hope will be able to provide a more robust answer to
some of the questions that have been raised.
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